FAST NEWS: BeiGene’s Lymphoma Drug Recommended to Enter European Regulator
The latest: BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Monday that its Zanubrutinib drug has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European…
RELATED ARTICLES
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
BYD drives ahead on European journey, undeterred by new tariffs
1211.HK 002594.SHE
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
